August 25, 2016 11:30 AM ET

Pharmaceuticals

Company Overview of Fresenius Kabi Pharmaceuticals Holding, Inc.

Company Overview

Fresenius Kabi Pharmaceuticals Holding, Inc. develops, manufactures, and markets injectable pharmaceutical products in North America. Its oncology products include Carboplatin for the advanced ovarian carcinoma; Doxorubicin for breast cancer; Fludarabine for B-cell chronic lymphocytic leukemia; Fluorouracil to inhibit the growth of cancer cells; Ifosfamide to treat germ cell testicular cancer; Irinotecan for cancer of the large intestine and rectum; Mesna for the side effects related to chemotherapy drugs; Paclitaxel Injection for the carcinoma of the ovary and non-small cell lung cancer; Cisplatin Injection for metastatic testicular tumors; Oxaliplatin; and Topotecan for Injection for small...

Else-Kroener-Strasse 1

Bad Homburg vdh

Bad Homburg,  61352

Germany

Founded in 1996

1,472 Employees

Phone:

49 6172 608 0

Key Executives for Fresenius Kabi Pharmaceuticals Holding, Inc.

Chief Executive Officer, President and Director
Chief Operating Officer and Executive Vice President
Age: 61
Chief Scientific Officer and Executive Vice President
Age: 55
Senior Vice President of Manufacturing
Age: 75
Executive Vice President and General Counsel
Age: 59
Compensation as of Fiscal Year 2016.

Fresenius Kabi Pharmaceuticals Holding, Inc. Key Developments

Fresenius Kabi Introduces Cisatracurium Besylate Injection

Fresenius Kabi has introduced its Cisatracurium Besylate Injection, a new specialty injectable product, in three presentations in the United States. The product is the generic equivalent of Nimbex and was approved by the US Food and Drug Administration. It is an intermediate-onset and intermediate-duration neuromuscular blocker for inpatient and outpatient use as an adjunct to general anaesthesia, to facilitate tracheal intubation. It is offered in three presentations: a 10 mg per 5 mL single use vial, a 20 mg per 10 mL multiple dose vial and a 200 mg per 20 mL single use vial. With the introduction of Cisatracurium, Fresenius Kabi delivers clinicians another choice in neuromuscular blockers while fostering commitment to provide customers access to one of the most comprehensive anaesthesia portfolios in the US.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fresenius Kabi Pharmaceuticals Holding, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.